By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -A boardroom shake-up at Novo Nordisk has handed ...

In the latest close session, Novo Nordisk (NVO) was down 1.59% at $52.05. The stock trailed the S&P 500, which registered a daily gain of 0.23%. On the other hand, the Dow registered a gain of 0.34%, ...

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...

Novo Nordisk will replace chair Helge Lund and six independent directors next month in a major boardroom shakeup following a ...

Novo Nordisk is undergoing significant leadership changes, including the replacement of its chair and six independent ...

Shares of Novo Nordisk have dropped as the company's largest investor, Novo Nordisk Foundation, calls for a board overhaul.

It was a deal with the Danish drugmaker that markets Ozempic and Wegovy that moved Omeros' stock price. Novo Nordisk ( NVO ...

Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the ...

Shares of Novo Nordisk fell around 3% on Wednesday, extending their losses from a day earlier, after the Wegovy maker's top ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

Omeros OMER stock surged 149% after announcing a $2.1 billion licensing deal with Novo Nordisk for its experimental drug ...